secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2024-04-26T23:59:59+00:00
Accession:  0000950170-24-049085
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Cytokinetics appoints Sung H. Lee as EVP, CFO effective May 8, 2024
-------------------------------------------------------------------

- Annual base salary of $550,000; target bonus 45% of base under corporate bonus plan.
- Signing bonus of $80,000; repayable if voluntarily resigns or terminated for cause within 12 months.
- Initial equity awards: $1,682,500 RSU, $1,682,500 stock options (Black-Scholes), $1,670,000 performance-based PSU.
- Lee replaces CEO Robert I. Blum, who had been serving as interim principal financial officer.
- Prior roles include CFO at Vir Biotechnology, MorphoSys AG, and Sangamo Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000095017024049085/0000950170-24-049085-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000095017024049085/cytk-20240423.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-049085

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer